These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28736218)

  • 1. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
    Nakamura Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M; Fujisawa Y
    Jpn J Clin Oncol; 2019 May; 49(5):431-437. PubMed ID: 30753621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
    Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
    J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Freeman-Keller M; Kim Y; Cronin H; Richards A; Gibney G; Weber JS
    Clin Cancer Res; 2016 Feb; 22(4):886-94. PubMed ID: 26446948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
    Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
    BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study.
    Okada N; Kawazoe H; Takechi K; Matsudate Y; Utsunomiya R; Zamami Y; Goda M; Imanishi M; Chuma M; Hidaka N; Sayama K; Kubo Y; Tanaka A; Ishizawa K
    Clin Ther; 2019 Jan; 41(1):59-67. PubMed ID: 30528047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
    J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study.
    Egami S; Kawazoe H; Hashimoto H; Uozumi R; Arami T; Sakiyama N; Ohe Y; Nakada H; Aomori T; Ikemura S; Fukunaga K; Yamaguchi M; Nakamura T
    Front Oncol; 2021; 11():618570. PubMed ID: 34123782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
    Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
    Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
    Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
    Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.